Patents by Inventor Janine Schuurman

Janine Schuurman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10882913
    Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: January 5, 2021
    Assignee: GENMAB B.V.
    Inventors: Marije Overdijk, Kristin Strumane, Rik Rademaker, Esther Breij, Janine Schuurman, Paul Parren
  • Patent number: 10865253
    Abstract: Novel rodent bispecific heterodimeric proteins, such as rodent bispecific antibodies, in vitro method for producing such, and uses thereof.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 15, 2020
    Assignee: GENMAB A/S
    Inventors: Aran F. Labrijn, Joyce I. Meesters, Janine Schuurman, Paul Parren, Anthony Armstrong, Matthew Bunce, Mark Chiu, Thomas Nesspor, Adam Zwolak
  • Publication number: 20200332022
    Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
    Type: Application
    Filed: February 6, 2020
    Publication date: October 22, 2020
    Applicant: GENMAB A/S
    Inventors: Aran Frank LABRIJN, Joyce I. MEESTERS, Joost J. NEIJSSEN, Edward Norbert VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
  • Patent number: 10759867
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: September 1, 2020
    Assignee: GENMAB B.V.
    Inventors: Paul Parren, Frank Beurskens, Rob N. De Jong, Aran Frank Labrijn, Janine Schuurman
  • Publication number: 20200270366
    Abstract: Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: October 29, 2019
    Publication date: August 27, 2020
    Inventors: Joost J. NEIJSSEN, Joyce I. MEESTERS, Bart DE GOEIJ, Aran Frank LABRIJN, Paul PARREN, Janine SCHUURMAN
  • Patent number: 10752695
    Abstract: The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 25, 2020
    Assignee: Genmab A/S
    Inventors: Jan Van De Winkel, Tom Vink, Janine Schuurman, Paul Parren, Rob Aalberse, Marijn Van Der Neut Kolfschoten
  • Publication number: 20200262932
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins
    Type: Application
    Filed: January 30, 2020
    Publication date: August 20, 2020
    Inventors: Aran Frank LABRIJN, Joyce I. MEESTERS, Ewald T. J. VAN DEN BREMER, Joost J. NEIJSSEN, Patrick VAN BERKEL, Bart DE GOEIJ, Tom VINK, Jan VAN DE WINKEL, Janine SCHUURMAN, Paul PARREN
  • Patent number: 10703818
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: July 7, 2020
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
  • Publication number: 20200199231
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Application
    Filed: December 4, 2019
    Publication date: June 25, 2020
    Inventors: Patrick ENGELBERTS, Esther BREIJ, Rik RADEMAKER, Isil ALTINTAS, David SATIJN, Sandra VERPLOEGEN, Riemke VAN DIJKHUIZEN RADERSMA, Edward VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
  • Publication number: 20200199229
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: August 19, 2019
    Publication date: June 25, 2020
    Inventors: Edward Norbert VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Isil ALTINTAS, Paul PARREN, Rik RADEMAKER
  • Publication number: 20200181277
    Abstract: As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.
    Type: Application
    Filed: February 12, 2018
    Publication date: June 11, 2020
    Inventors: Frank BEURSKENS, Marije OVERDIJK, Annieck M. DIKS, Rob DE JONG, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN
  • Publication number: 20200165352
    Abstract: Antibody variants comprising one or more mutations in the Fc region, particularly anti-CD38 antibodies comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index.
    Type: Application
    Filed: February 10, 2020
    Publication date: May 28, 2020
    Inventors: Bart De GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David P.E. SATIJN, Tahamtan AHMADI
  • Publication number: 20200123237
    Abstract: The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding.
    Type: Application
    Filed: May 17, 2017
    Publication date: April 23, 2020
    Applicant: Genmab B.V.
    Inventors: Annemarie KUIPERS, Kok van KESSEL, Frank BEURSKENS, Rob de JONG, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN, Jos van STRIJP, Suzan ROOIJAKKERS
  • Publication number: 20200123255
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: September 25, 2019
    Publication date: April 23, 2020
    Inventors: Edward VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Paul PARREN
  • Patent number: 10597464
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: March 24, 2020
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
  • Publication number: 20200087407
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 19, 2020
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Patent number: 10590206
    Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: March 17, 2020
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce Meesters, Joost J. Neijssen, Edward Norbert Van Den Brink, Janine Schuurman, Paul Parren
  • Publication number: 20200079872
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: August 23, 2019
    Publication date: March 12, 2020
    Inventors: Joost J. NEIJSSEN, Bart DE GOEIJ, Edward Norbert VAN DEN BRINK, Aran Frank LABRIJN, Rene HOET, Janine SCHUURMAN, Paul PARREN, Jan VAN DE WINKEL
  • Publication number: 20200048304
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Application
    Filed: May 30, 2019
    Publication date: February 13, 2020
    Inventors: Michael GRAMER, Amitava KUNDU, Ewald T. J. VAN DEN BREMER, Muriel VAN KAMPEN, Patrick PRIEM, Aran Frank LABRIJN, Joyce I. MEESTERS, Joost J. NEIJSSEN, Janine SCHUURMAN, Paul PARREN, Patrick VAN BERKEL, Werner L. VOS, Arnout F. GERRITSEN
  • Patent number: 10544220
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 28, 2020
    Assignee: GENMAB A/S
    Inventors: Patrick Engelberts, Esther Breij, Rik Rademaker, Isil Altintas, David Satijn, Sandra Verploegen, Riemke Van Dijkhuizen Radersma, Edward Van Den Brink, Janine Schuurman, Paul Parren